Heart failure & cardiomyopathies
Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction
Authors' conclusion
A composite of ARNi+BB+SGLT2i or ARNi+BB+MRA+SGLT2i was the most effective at improving quality of life in patients with HFrEF.
Study context
- Population
- Adults with heart failure with reduced ejection fraction (HFrEF)
- Participants
- 41,145 adults41 RCTs
- Comparison
- Pharmacological HFrEF therapies and combinations vs each other
- Outcome
- Change in quality of life (KCCQ and MLHFQ), expressed as MD
Methodological detailsfrequentist
- Frequentist
Pooled result
As reported in the abstract
Change in quality of life (combinations)
MD
- ARNi+BB+SGLT2i · most effective
- +5.3 (CI +0.4, +10.3)
- ARNi+BB+MRA+SGLT2i · not statistically significant
- +7.1 (CI −1.0 to +15.2)
- ACE inhibitor+BB+MRA+SGLT2i · not statistically significant
- +5.3 (CI −2.6, to +13.3)
- ACE inhibitor+BB+MRA+ivabradine · not statistically significant
- +5.2 (CI −3.1 to +13.6)
Further pooled results
Change in quality of life (individual treatments)
| MD (CI) | |
|---|---|
| SGLT2i | +3.4 (+1.4 to +5.30) |
| Ivabradine | +3.3 (+0.1 to +6.4) |
| ARNi | +2.6 (−3.2 to +8.5) |
| MRA | +1.8 (−4.8 to +8.4) |
Original publication
Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction. Circ Heart Fail. Published 5 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →